Cargando…

A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia

Several PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity. We have recently reported promising efficacy results treating chronic lymphocytic leukemia (CLL) patients with combination therapy with the PI3K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gadi, Deepti, Griffith, Alec, Tyekucheva, Svitlana, Wang, Zixu, Rai, Vanessa, Vartanov, Alexander, Thrash, Emily, Fernandes, Stacey M, Lehmberg, Timothy Z., Lee, Brandon, Martindale, Stephen P, Machado, John-Hanson, Odejide, Oreofe, Armand, Philippe, Fisher, David C., Arnason, Jon, Davids, Matthew S., Lederer, James A, Brown, Jennifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891037/ https://www.ncbi.nlm.nih.gov/pubmed/34743191 http://dx.doi.org/10.1038/s41375-021-01441-9

Ejemplares similares

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
por: Davids, Matthew S., et al.
Publicado: (2020)

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
por: Gadi, Deepti, et al.
Publicado: (2023)

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells
por: Kawada, Jun‐ichi, et al.
Publicado: (2018)

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
por: Rodrigues, Daniel A., et al.
Publicado: (2019)

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
por: Goldsmith, Scott R, et al.
Publicado: (2023)

Development and validation of an UPLC-ESI-MS/MS method for quantification of duvelisib in plasma: application to pharmacokinetic study in rats
por: Darwish, Ibrahim A., et al.
Publicado: (2023)

Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
por: Kuczmarski, Thomas M., et al.
Publicado: (2022)

Effect of Duvelisib, a Selective PI3K Inhibitor on Seizure Activity in Pentylenetetrazole-Induced Convulsions Animal Model
por: Abdolrahmani, Mahnaz, et al.
Publicado: (2023)

Meaningful changes in end-of-life care among patients with myeloma
por: Odejide, Oreofe O., et al.
Publicado: (2018)

Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway
por: Li, Xiaohe, et al.
Publicado: (2023)

Integrating diverse genomic data using gene sets
por: Tyekucheva, Svitlana, et al.
Publicado: (2011)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018)

A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
por: Sayed, Ahmed Y, et al.
Publicado: (2021)

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS
por: Zinzani, P. L., et al.
Publicado: (2022)

Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib
por: Shah, Ankit, et al.
Publicado: (2021)

P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY
por: Mehta-Shah, Neha, et al.
Publicado: (2023)

A Macaque's-Eye View of Human Insertions and Deletions: Differences in Mechanisms
por: Kvikstad, Erika M, et al.
Publicado: (2007)

Early Palliative Care in Acute Myeloid Leukemia
por: Potenza, Leonardo, et al.
Publicado: (2022)

Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
por: Flinn, Ian W., et al.
Publicado: (2018)

Genomic Environment Predicts Expression Patterns on the Human Inactive X Chromosome
por: Carrel, Laura, et al.
Publicado: (2006)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials
por: Wang, Zhongwang, et al.
Publicado: (2023)

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
por: Merryman, Reid W., et al.
Publicado: (2023)

P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)
por: Vorobyev, V., et al.
Publicado: (2022)

Human-macaque comparisons illuminate variation in neutral substitution rates
por: Tyekucheva, Svitlana, et al.
Publicado: (2008)

Perceptions of Hope Among Bereaved Caregivers of Cancer Patients Who Received Early Palliative Care: A Content and Lexicographic Analysis
por: Bigi, Sarah, et al.
Publicado: (2022)

Distinct Injury Responsive Regulatory T Cells Identified by Multi-Dimensional Phenotyping
por: Guo, Fei, et al.
Publicado: (2022)

Establishing the baseline level of repetitive element expression in the human cortex
por: Tyekucheva, Svitlana, et al.
Publicado: (2011)

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
por: Merryman, Reid W., et al.
Publicado: (2022)

Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer
por: Börnigen, Daniela, et al.
Publicado: (2016)

Concurrent Lymphoma and COVID-19: Diagnostic and Therapeutic Challenges of High-Grade Lymphoma and COVID-19
por: Hundal, Jasmin, et al.
Publicado: (2022)

Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review
por: Vartanov, Alexander, et al.
Publicado: (2021)

Haematopoietic Stem Cell Transplantation for Primary Haemophagocytic Lymphohistiocytosis
por: Lehmberg, Kai, et al.
Publicado: (2019)

Sequestration of phosphoinositides by mutated MARCKS effector domain inhibits stimulated Ca(2+) mobilization and degranulation in mast cells
por: Gadi, Deepti, et al.
Publicado: (2011)

Perceptions of Death Among Patients with Advanced Cancer Receiving Early Palliative Care and Their Caregivers: Results from a Mixed-Method Analysis
por: Bigi, Sarah, et al.
Publicado: (2022)

A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
por: Proudman, David, et al.
Publicado: (2022)

An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia
por: Bell, Stephen, et al.
Publicado: (2021)

Changes in Cancer Patients' and Caregivers' Disease Perceptions While Receiving Early Palliative Care: A Qualitative and Quantitative Analysis
por: Borelli, Eleonora, et al.
Publicado: (2021)

Pharmacological Neuroenhancement: teachers’ knowledge and attitudes–Results from a survey study among teachers in Germany
por: Franke, Andreas G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j7m801415cjkr60186nfr5rv74